Biogen Pharmachem
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
March 23 (Reuters) - Biogen Pharmachem Industries Ltd BIOG.BO:
APPROVES BONUS SHARE ISSUE IN RATIO OF 1:6
Source text: ID:nBSEb1wVdh
Further company coverage: BIOG.BO
(([email protected];))
March 23 (Reuters) - Biogen Pharmachem Industries Ltd BIOG.BO:
APPROVES BONUS SHARE ISSUE IN RATIO OF 1:6
Source text: ID:nBSEb1wVdh
Further company coverage: BIOG.BO
(([email protected];))
Feb 24 (Reuters) - Biogen Pharmachem Industries Ltd BIOG.BO:
BIOGEN PHARMACHEM INDUSTRIES LTD - TO CONSIDER DECLARATION OF ISSUE OF BONUS SHARES
Source text: ID:nBSE8mj31N
Further company coverage: BIOG.BO
(([email protected];))
Feb 24 (Reuters) - Biogen Pharmachem Industries Ltd BIOG.BO:
BIOGEN PHARMACHEM INDUSTRIES LTD - TO CONSIDER DECLARATION OF ISSUE OF BONUS SHARES
Source text: ID:nBSE8mj31N
Further company coverage: BIOG.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Biogen Pharmachem do?
Sun Techno Overseas Ltd is a company engaged in share trading, stock broking, consulting, commodities trading in agro-based and precious metals, and diversifying into the power sector with wind power generation plant.
Who are the competitors of Biogen Pharmachem?
Biogen Pharmachem major competitors are Phoenix Overseas, Contil India, Gujarat Cotex, Ecofinity Atomix, Ushdev International, AG Universal, Yarn Syndicate. Market Cap of Biogen Pharmachem is ₹35 Crs. While the median market cap of its peers are ₹35 Crs.
Is Biogen Pharmachem financially stable compared to its competitors?
Biogen Pharmachem seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Biogen Pharmachem pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Biogen Pharmachem latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Biogen Pharmachem allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Biogen Pharmachem balance sheet?
Balance sheet of Biogen Pharmachem is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Biogen Pharmachem improving?
The profit is oscillating. The profit of Biogen Pharmachem is ₹0.96 Crs for TTM, -₹0.29 Crs for Mar 2025 and ₹1.93 Crs for Mar 2024.
Is the debt of Biogen Pharmachem increasing or decreasing?
Yes, The net debt of Biogen Pharmachem is increasing. Latest net debt of Biogen Pharmachem is -₹0.32 Crs as of Mar-26. This is greater than Mar-25 when it was -₹3.98 Crs.
Is Biogen Pharmachem stock expensive?
Biogen Pharmachem is not expensive. Latest PE of Biogen Pharmachem is 41.63, while 3 year average PE is 63.77. Also latest EV/EBITDA of Biogen Pharmachem is 68.48 while 3yr average is 210.
Has the share price of Biogen Pharmachem grown faster than its competition?
Biogen Pharmachem has given lower returns compared to its competitors. Biogen Pharmachem has grown at ~-58.09% over the last 1yrs while peers have grown at a median rate of -8.65%
Is the promoter bullish about Biogen Pharmachem?
There is Insufficient data to gauge this.
Are mutual funds buying/selling Biogen Pharmachem?
There is Insufficient data to gauge this.